Notice of Correction to NOT-OD-20-119, NOT-OD-20-120, NOT-OD-20-121 Eligibility Section
Notice Number:
NOT-OD-20-138

Key Dates

Release Date:

June 30, 2020

Related Announcements

NOT-OD-20-119 - Notice of Special Interest (NOSI): Emergency Competitive Revisions for Social, Ethical, and Behavioral Implications (SEBI) Research on COVID-19 Testing among Underserved and/or Vulnerable Populations

NOT-OD-20-120 -Notice of Special Interest (NOSI): Emergency Competitive Revisions for Community-Engaged Research on COVID-19 Testing among Underserved and/or Vulnerable Populations

NOT-OD-20-121 - Notice of Special Interest (NOSI): Limited Competition for Emergency Competitive Revisions for Community-Engaged Research on COVID-19 Testing among Underserved and/or Vulnerable Populations

NOT-HL-20-803 - Notice of NHLBI Participation in NOT-OD-20-119

NOT-HL-20-804 -Notice of NHLBI Participation in NOT-OD-20-120

NOT-HL-20-805 - Notice of NHLBI Participation in NOT-OD-20-121

Issued by

Office of The Director, National Institutes of Health (OD)

Purpose

The purpose of this notice is to inform potential applicants of correction to the Eligibility section of:

NOT-OD-20-119 "Notice of Special Interest (NOSI): Emergency Competitive Revisions for Social, Ethical, and Behavioral Implications (SEBI) Research on COVID-19 Testing among Underserved and/or Vulnerable Populations"

NOT-OD-20-120 "Notice of Special Interest (NOSI): Emergency Competitive Revisions for Community-Engaged Research on COVID-19 Testing among Underserved and/or Vulnerable Populations"

NOT-OD-20-121 "Notice of Special Interest (NOSI): Limited Competition for Emergency Competitive Revisions for Community-Engaged Research on COVID-19 Testing among Underserved and/or Vulnerable Populations"

These Notices of Special Interest have been modified as follows:

Eligibility

Added: "Competitive revision applications to this NOSI may not propose new foreign components and may not request additional funding for existing foreign components.”

Furthermore, in NOT-OD-20-121 "Notice of Special Interest (NOSI): Limited Competition for Emergency Competitive Revisions for Community-Engaged Research on COVID-19 Testing among Underserved and/or Vulnerable Populations",NIDA corrects the list of eligible grant programs to add "Coordinating Center to Support NIDA Rural Opioid HIV and Comorbidity Initiative (RFA-DA-19-004)", and to correct the listed FOAs for "Limited Competition Cohort Studies of HIV/AIDS and Substance Abuse" adding RFA-DA-17-019; PAS-DA-12-222, and for "NIDA Research Center of Excellence Grant Program" to include PAR-19-259; PAR-18-224; PAR-16-009.

Currently reads:

“NIDA Eligible Grants are funded under the following Funding Opportunity Announcements:

  • HIV, HCV and Related Comorbidities in Rural Communities Affected by Opioid Injection Drug Epidemics in the United States: Building Systems for Prevention, Treatment and Control (RFA-DA-17-014)
  • Hepatitis C Virus (HCV) Advanced Molecular Detection in Support of Systems for Prevention, Treatment and Control of HIV, HCV and Related Comorbidities in Rural Communities Affected by Opioid Injection Drug Epidemics in the United States (RFA-DA-17-023)
  • Limited Competition Cohort Studies of HIV/AIDS and Substance Abuse (RFA-DA-20-005; RFA-DA-18-011)
  • NIDA Core “Center of Excellence” Grant Program (PAR-17-121; PAR-14-186)
  • HEAL Initiative: Justice Community Opioid Innovation Network (JCOIN): Methodology and Advanced Analytics Resource Center (RFA-DA-19-023); Clinical Research Centers (RFA-DA-19-025); Coordination and Translation Center (RFA-DA-19-024)
  • HEAL Initiative: Preventing Opioid Use Disorder in Older Adolescents and Young Adults (ages 16-30) (RFA-DA-19-035); Coordinating Center (RFA-DA-19-034)
  • HEAL Initiative: HEALthy Brain and Child Development Study (HEALthy BCD) (RFA-DA-19-036, RFA-DA-19-029)
  • HEALing Communities Study: Developing and Testing an Integrated Approach to Address the Opioid Crisis: Research Sites (RFA-DA-19-016); Data Coordinating Center (RFA-DA-19-017)
  • Limited Competition for Adolescent Brain Cognitive Development (ABCD) Study – Linked Research Project Sites (RFA-DA-20-002); Data Analysis, Informatics and Resource Center (RFA-DA-20-003); Coordinating Center (RFA-DA-20-004)
  • The National Drug Abuse Treatment Clinical Trials Network (RFA-DA-20-024; RFA-DA-15-008)
  • NIDA Research Center of Excellence Grant Program (PAR-18-224; PAR-18-224)”

Modified to read:

“NIDA Eligible Grants are funded under the following Funding Opportunity Announcements:

  • HIV, HCV and Related Comorbidities in Rural Communities Affected by Opioid Injection Drug Epidemics in the United States: Building Systems for Prevention, Treatment and Control? (RFA-DA-17-014)
  • Hepatitis C Virus (HCV) Advanced Molecular Detection in Support of Systems for Prevention, Treatment and Control of HIV, HCV and Related Comorbidities in Rural Communities Affected by Opioid Injection Drug Epidemics in the United States (RFA-DA-17-023)
  • Coordinating Center to Support NIDA Rural Opioid HIV and Comorbidity Initiative (RFA-DA-19-004)
  • Limited Competition Cohort Studies of HIV/AIDS and Substance Abuse (RFA-DA-20-005; RFA-DA-18-011; RFA-DA-17-019; PAS-DA-12-222)
  • NIDA Core “Center of Excellence” Grant Program (PAR-17-121; PAR-14-186)
  • HEAL Initiative: Justice Community Opioid Innovation Network (JCOIN): Methodology and Advanced Analytics Resource Center (RFA-DA-19-023); Clinical Research Centers (RFA-DA-19-025); Coordination and Translation Center (RFA-DA-19-024)
  • HEAL Initiative: Preventing Opioid Use Disorder in Older Adolescents and Young Adults (ages 16-30) (RFA-DA-19-035); Coordinating Center (RFA-DA-19-034)
  • HEAL Initiative: HEALthy Brain and Child Development Study (HEALthy BCD) (RFA-DA-19-036, RFA-DA-19-029)
  • HEALing Communities Study: Developing and Testing an Integrated Approach to Address the Opioid Crisis: Research Sites (RFA-DA-19-016); Data Coordinating Center (RFA-DA-19-017)
  • Limited Competition for Adolescent Brain Cognitive Development (ABCD) Study – Linked Research Project Sites (RFA-DA-20-002); Data Analysis, Informatics and Resource Center (RFA-DA-20-003); Coordinating Center (RFA-DA-20-004)
  • The National Drug Abuse Treatment Clinical Trials Network (RFA-DA-20-024; RFA-DA-15-008)
  • NIDA Research Center of Excellence Grant Program (PAR-19-259; PAR-18-224; PAR-16-009)”

All other aspects of the FOAs remain unchanged.

Inquiries

Please direct all inquiries to:

Please direct all inquiries regarding this Notice to the point(s) of contact listed in the respective NOSI.


Weekly TOC for this Announcement
NIH Funding Opportunities and Notices